GLUE
Monte Rosa Therapeutics Inc
10.20$
+3.0%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
Monte Rosa Therapeutics Inc (GLUE) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -81 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.4 | -4.2 | -6.9 | -8.6 | -14 | -14 | -18 | -14 | -27 | -21 | -21 | -24 | -23 | -25 | -25 | 30 | -38 | -28 | -21 | 129 | -45 | -35 | 100 | -43 | -37 | -81 | -61 | |
| 0.1 | 0.1 | 0.2 | 0.2 | 0.3 | 0.5 | 0.6 | 0.8 | 0.8 | 0.9 | 1.0 | 1.1 | 1.2 | 1.4 | 1.8 | 1.8 | 1.9 | 2.1 | 2.1 | 2.1 | 2.0 | 2.1 | 2.1 | 2.1 | 2.0 | 3.9 | 10 | |
| 0.0 | 0.1 | 0.0 | 0.2 | 0.3 | 1.0 | 2.1 | 1.9 | 2.3 | 2.9 | 3.2 | 3.3 | 4.0 | 4.2 | 4.5 | 4.1 | 4.9 | 4.5 | 4.3 | 4.5 | 5.3 | 4.9 | 4.4 | 4.3 | 5.9 | 12 | 27 | |
| 0.0 | 0.1 | 0.0 | – | 1.2 | 1.0 | 2.1 | 1.9 | 2.1 | 2.9 | 3.2 | 3.3 | 4.1 | 2.7 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.8 | 1.0 | -0.6 | 3.0 | -3.0 | 3.3 | -0.6 | 6.6 | -6.7 | 1.2 | 1.3 | 2.1 | 4.6 | 5.7 | 4.4 | 58 | -13 | -2.9 | -2.4 | 110 | -99 | -29 | 122 | -3.4 | 0.1 | -7.6 | 111 | |
| 0.0 | 1.3 | 0.9 | 1.2 | 2.2 | 2.7 | 1.8 | 3.1 | 1.6 | 2.6 | 1.4 | 7.3 | 9.2 | 6.5 | 1.7 | 1.7 | 1.4 | 2.0 | 0.4 | 0.2 | 1.6 | 1.7 | 0.7 | 0.8 | 1.9 | 6.6 | 9.9 | |
| 0.0 | -1.3 | -0.9 | -1.2 | -2.2 | -2.7 | -1.7 | -3.0 | -181 | -14 | 29 | -54 | 20 | 19 | 36 | 14 | 9.9 | -61 | 38 | -31 | -100 | 25 | 38 | -65 | -261 | -290 | -578 | |
| 0.0 | -0.2 | – | – | -0.2 | 0.0 | – | 0.2 | 0.2 | 0.1 | 0.1 | 21 | 0.0 | – | – | – | – | – | – | 0.0 | – | – | – | -0.4 | – | – | – | |
| 143 | 12 | 48 | 0.0 | 143 | 205 | 29 | -0.1 | 0.2 | 0.1 | -0.2 | 20 | 0.0 | 1.2 | 1.1 | 25 | 0.2 | 98 | 0.0 | 0.6 | 0.0 | 0.4 | 0.3 | 30 | 328 | 332 | 690 | |
| -3.4 | 6.9 | 40 | -9.8 | 127 | 189 | 10.0 | -21 | -208 | -35 | 9.7 | -57 | -3.1 | -5.8 | 12 | 69 | -28 | 9.1 | 17 | 99 | -146 | -9.0 | 139 | -78 | 30 | -40 | 51 | |
| -3.4 | -5.5 | -7.8 | -9.8 | -16 | -16 | -20 | -17 | -29 | -23 | -22 | -31 | -33 | -32 | -26 | 28 | -40 | -30 | -21 | 129 | -47 | -36 | 100 | -44 | -39 | -88 | -71 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.